Issue navigation
Volume 112, Issue 12, December 2020
Editorials
Use of Positron Emission Tomography Imaging: Another Nonbiological Source of Racial Disparities in US Cancer Care
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 12, December 2020, Pages 1177–1178, https://doi.org/10.1093/jnci/djaa035
Genetic Testing May Help Reduce Breast Cancer Disparities for African American Women
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 12, December 2020, Pages 1179–1180, https://doi.org/10.1093/jnci/djaa042
Trastuzumab: Weighing the Benefits and the Risks
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 12, December 2020, Pages 1181–1182, https://doi.org/10.1093/jnci/djaa055
Commentary
Personalized Cancer Follow-Up Care Pathways: A Delphi Consensus of Research Priorities
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 12, December 2020, Pages 1183–1189, https://doi.org/10.1093/jnci/djaa053
Review
BRCA1 Promoter Methylation and Clinical Outcomes in Ovarian Cancer: An Individual Patient Data Meta-Analysis
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 12, December 2020, Pages 1190–1203, https://doi.org/10.1093/jnci/djaa070
Articles
Ethnic Disparities in Imaging Utilization at Diagnosis of Non-Small Cell Lung Cancer
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 12, December 2020, Pages 1204–1212, https://doi.org/10.1093/jnci/djaa034
Contribution of Germline Predisposition Gene Mutations to Breast Cancer Risk in African American Women
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 12, December 2020, Pages 1213–1221, https://doi.org/10.1093/jnci/djaa040
Impact of Stopping Trastuzumab in Early Breast Cancer: A Population-Based Study in Ontario, Canada
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 12, December 2020, Pages 1222–1230, https://doi.org/10.1093/jnci/djaa054
The Contribution of Germline Predisposition Gene Mutations to Clinical Subtypes of Invasive Breast Cancer From a Clinical Genetic Testing Cohort
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 12, December 2020, Pages 1231–1241, https://doi.org/10.1093/jnci/djaa023
Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 12, December 2020, Pages 1242–1250, https://doi.org/10.1093/jnci/djaa030
Hospice Utilization in Elderly Patients With Brain Metastases
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 12, December 2020, Pages 1251–1258, https://doi.org/10.1093/jnci/djaa036
Mitochondrial DNA Haplogroups and Susceptibility to Neuroblastoma
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 12, December 2020, Pages 1259–1266, https://doi.org/10.1093/jnci/djaa024
Evaluating Treatment Tolerability in Cancer Clinical Trials Using the Toxicity Index
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 12, December 2020, Pages 1266–1274, https://doi.org/10.1093/jnci/djaa028
Brief Communication
Radiation Treatment, ATM, BRCA1/2, and CHEK2*1100delC Pathogenic Variants and Risk of Contralateral Breast Cancer
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 12, December 2020, Pages 1275–1279, https://doi.org/10.1093/jnci/djaa031
Correspondence
RE: Concurrent Opioid and Benzodiazepine Prescriptions Among Older Women Diagnosed With Breast Cancer
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 12, December 2020, Page 1279, https://doi.org/10.1093/jnci/djaa145
Response
Response to Strassels and Durham
JNCI: Journal of the National Cancer Institute, Volume 112, Issue 12, December 2020, Page 1280, https://doi.org/10.1093/jnci/djaa146
